2. Search Result
Search Result
Results for "

CSFs

" in MedChemExpress (MCE) Product Catalog:

180

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

3

Biochemical Assay Reagents

5

Peptides

30

Inhibitory Antibodies

11

Natural
Products

26

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12768
    Sotuletinib
    35+ Cited Publications

    BLZ945

    		 c-Fms Infection Neurological Disease Cancer
    Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research .
    Sotuletinib
  • HY-12768A
    Sotuletinib hydrochloride
    35+ Cited Publications

    BLZ945 hydrochloride

    		 c-Fms Cancer
    Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. .
    Sotuletinib hydrochloride
  • HY-P99207
    Lenzilumab
    1 Publications Verification

    KB 003

    		 SARS-CoV Cancer
    Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
    Lenzilumab
  • HY-109052
    Atabecestat
    1 Publications Verification

    JNJ-54861911

    		 Beta-secretase Neurological Disease
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
    Atabecestat
  • HY-P990125
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)

    		c-Fms Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Anti-Mouse (CSF1R/CD115) Antibody (AFS98) is an anti-mouse CSF1R IgG2a antibody inhibitor derived from rats. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) inhibits M-CSF-dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) can be used for the researches of inflammation, metabolic disease, cardiovascular disease and neurological disease, such as such as stroke, diabetes and arthritis .
    Anti-Mouse CSF1R/CD115 Antibody (AFS98)
  • HY-P990043
    Iluzanebart

    VGL101

    		 Ser/Thr Kinase TREM receptor Inflammation/Immunology
    Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
    Iluzanebart
  • HY-P99245
    Emactuzumab

    RG 7155; RO 5509554

    		 c-Fms Cancer
    Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
    Emactuzumab
  • HY-P99452
    Axatilimab

    SNDX-6352

    		 c-Fms Inflammation/Immunology Cancer
    Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
    Axatilimab
  • HY-124526
    Chiauranib

    Ibcasertib; CS2164

    		 PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis Cancer
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .
    Chiauranib
  • HY-P99368
    Lacnotuzumab

    MCS110

    		 c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
    Lacnotuzumab
  • HY-101774
    CSF1R-IN-1
    1 Publications Verification

    		 c-Fms Cancer
    CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
    CSF1R-IN-1
  • HY-P990094
    Trabikibart

    CSL311

    		 c-Fms Inflammation/Immunology
    Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
    Trabikibart
  • HY-101768
    PRN1371
    1 Publications Verification

    		 FGFR c-Fms Cancer
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
    PRN1371
  • HY-B0538A
    Pemirolast potassium

    TWT-8152; BMY 26517

    		 Histamine Receptor Cardiovascular Disease Inflammation/Immunology
    Pemirolast potassium is an orally active antiallergic agent. Pemirolast potassium attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast potassium can be used for bronchial asthma and conjunctivitis research - .
    Pemirolast potassium
  • HY-10204
    OSI-930
    4 Publications Verification

    		 c-Kit VEGFR c-Fms Apoptosis Cancer
    OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
    OSI-930
  • HY-122767
    Romurtide

    Muroctasin

    		 Interleukin Related Inflammation/Immunology
    Romurtide (Muroctasin), a synthetic muramyl dipeptide derivative, is a cytokines inducer. Romurtide can increase peripheral neutrophils and monocytes in vivo and enhance production of colony-stimulating factors (CSFs), IL-1 and IL-6 in vitro .
    Romurtide
  • HY-117244
    AZD7507
    2 Publications Verification

    		 c-Fms Cancer
    AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
    AZD7507
  • HY-P99031
    Mavrilimumab

    CAM 3001

    		 c-Fms Cardiovascular Disease Inflammation/Immunology
    Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
    Mavrilimumab
  • HY-126297
    c-Fms-IN-10

    		c-Fms Inflammation/Immunology Cancer
    c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity .
    c-Fms-IN-10
  • HY-P99879
    Efbemalenograstim alfa

    Benegrastim; Bineuta; F 627

    		 STAT Inflammation/Immunology
    Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
    Efbemalenograstim alfa
  • HY-P99779
    Plonmarlimab

    TJ003234; TJM2

    		 c-Fms SARS-CoV Infection Inflammation/Immunology
    Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .
    Plonmarlimab
  • HY-P99795
    Otilimab

    GSK 3196165; MOR103

    		 c-Fms Inflammation/Immunology
    Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
    Otilimab
  • HY-136362
    ARRY-382

    		c-Fms Inflammation/Immunology Cancer
    ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .
    ARRY-382
  • HY-W014134
    p-APMSF hydrochloride

    p-Amidinophenylmethylsulfonylfluoride hydrochloride

    		 Ser/Thr Protease Inflammation/Immunology
    p-APMSF (p-Amidinophenylmethylsulfonylfluoride) hydrochloride is a serine protease and trypsin inhibitor with the characteristic of rapid onset of action. p-APMSF hydrochloride reduces the enzymatic hydrolysis of recombinant human G-CSF in rat pulmonary mucosa. Combined intratracheal treatment with p-APMSF hydrochloride and Laureth-9 significantly enhances its absorption efficiency in rat lungs. Following intranasal administration, p-APMSF hydrochloride does not increase the concentration of recombinant human G-CSF in rat plasma, nor does it alter the effect of G-CSF on inducing an increase in total white blood cell count .
    p-APMSF hydrochloride
  • HY-160842
    CSF1R-IN-24

    		c-Fms Neurological Disease
    CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) .
    CSF1R-IN-24
  • HY-112451
    cFMS Receptor Inhibitor II

    		c-Fms Inflammation/Immunology
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine .
    cFMS Receptor Inhibitor II
  • HY-P99134
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
    1 Publications Verification

    		 c-Fms Infection Inflammation/Immunology Cancer
    Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
  • HY-122906
    JTE-952

    		c-Fms Inflammation/Immunology
    JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC50 values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .
    JTE-952
  • HY-P991048
    AMG-820

    		c-Fms Cancer
    AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .
    AMG-820
  • HY-119942
    c-Fms-IN-8

    		c-Fms Cancer
    c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM .
    c-Fms-IN-8
  • HY-159108
    AZ683

    		c-Fms Cardiovascular Disease
    AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (Ki=8 nM; IC50=6 nM). AZ683 has good oral bioavailability. [ 11C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .
    AZ683
  • HY-132935
    BPR1R024

    		c-Fms Inflammation/Immunology Cancer
    BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology .
    BPR1R024
  • HY-161025
    SYHA1813

    		c-Fms VEGFR Cancer
    SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM .
    SYHA1813
  • HY-147615
    CSF1R-IN-12

    		c-Fms Cancer
    CSF1R-IN-12 (compound 1) is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases .
    CSF1R-IN-12
  • HY-P990257
    Anti-Mouse CSF1 Antibody (5A1)

    		c-Fms Cancer
    Anti-Mouse CSF1 Antibody (5A1) is a rat-derived anti-mouse CSF1 IgG1 κ type antibody inhibitor. Anti-Mouse CSF1 Antibody (5A1) can inhibit cells proliferation and macrophage-induced invasion. Anti-Mouse CSF1 Antibody (5A1) shows potent anti-tumor effect in various tumor models, such as neuroblastoma .
    Anti-Mouse CSF1 Antibody (5A1)
  • HY-12938
    AMG-8718

    		Beta-secretase Neurological Disease
    AMG-8718 is a potent, selective and orally active BACE1 inhibitor with IC50 values of 0.0007, 0.005 µM for BACE1 and BACE2, respectively. AMG-8718 significantly decreases Aβ40 levels in the CSF and brain .
    AMG-8718
  • HY-139990
    CSF1R-IN-3
    1 Publications Verification

    		 c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .
    CSF1R-IN-3
  • HY-101526
    GENZ-882706

    RA03546849

    		 c-Fms Inflammation/Immunology
    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
    GENZ-882706
  • HY-P99307
    Namilumab

    AMG-203; Anti-Human CSF2 Recombinant Antibody

    		 c-Fms Inflammation/Immunology
    Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
    Namilumab
  • HY-19545B
    (S)-SCH-23390 hydrochloride

    SCH-23388 hydrochloride

    		 Dopamine Receptor Neurological Disease
    (S)-SCH-23390 hydrochloride is the S-enantiomer of SCH-23390 (HY-19545). SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively) .
    (S)-SCH-23390 hydrochloride
  • HY-144041
    CSF1R-IN-5

    		c-Fms Cancer
    CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .
    CSF1R-IN-5
  • HY-147609
    CSF1R-IN-8

    		c-Fms Cancer
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM .
    CSF1R-IN-8
  • HY-147611
    CSF1R-IN-10

    		c-Fms Cancer
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM .
    CSF1R-IN-10
  • HY-168954
    CSF1R-IN-26

    		c-Fms Apoptosis Akt ERK STAT Inflammation/Immunology Cancer
    CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
    CSF1R-IN-26
  • HY-155001
    CSF1R-IN-15

    		c-Fms Others
    CSF1R-IN-15 (compound 23) is an inhibitor targeting CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R is crucial for the differentiation, proliferation, and survival of macrophages .
    CSF1R-IN-15
  • HY-159503A
    Segigratinib hydrochloride

    3D185; HH185

    		 FGFR c-Fms Cancer
    Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .
    Segigratinib hydrochloride
  • HY-RS16853
    Csf1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Csf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Csf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Csf1 Mouse Pre-designed siRNA Set A
    Csf1 Mouse Pre-designed siRNA Set A
  • HY-P990975
    Birinkibart

    		Transmembrane Glycoprotein Inflammation/Immunology
    HY-P990975 is an CSF2RB-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Birinkibart
  • HY-12768B
    Sotuletinib dihydrochloride

    BLZ945 dihydrochloride

    		 c-Fms Neurological Disease Cancer
    Sotuletinib (BLZ945) dihydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib dihydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research .
    Sotuletinib dihydrochloride
  • HY-125393
    Leustroducsin A

    		c-Fms Cancer
    Leustroducsin A is a colony-stimulating factor (CSF) inducer. Leustroducsin A induces production of CSF by bone marrowstromal cells .
    Leustroducsin A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: